Every year nearly 50.000 dialysis patients worldwide receive a kidney transplant, but depending on the type of donor between 20 to 60% of the implanted kidneys are not working .

Aspiring new drugs face long and stringent tests on safety and effectiveness before making it to market. And rightly so. But giving drugs special designations that bring with them the right incentives can help bring them to patient.